Prognosis
Russian Covid Vaccine’s Effectiveness Confirmed by Expert Review
- Sputnik V interim Phase 3 results show 91.6% efficacy
- Vaccine may work well against new strains, developer claims
Sputnik V showed efficacy of 91.6%, validating claims by the developers last year.
Photographer: Andrey Rudakov/BloombergThis article is for subscribers only.
Russia’s Sputnik V vaccine provided strong protection against Covid-19 in an interim analysis of an advanced clinical trial, while its backers said it appears to work against new strains of the virus.
The vaccine was well-tolerated and worked in the elderly as well, according to the peer-reviewed findings, which were published Tuesday in the medical journal The Lancet. Sputnik V showed efficacy of 91.6%, validating claims by the developers last year.